Basic Information
| LncRNA/CircRNA Name | GLIS3-AS1 |
| Synonyms | NA |
| Region | GRCh38_9:3898642-3901248 |
| Ensemble | ENSG00000237009 |
| Refseq | NR_026663 |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | Drug | |||
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | bladder cancer |
| ICD-0-3 | C67 |
| Methods | other |
| Sample | TCGA |
| Expression Pattern | up-regulated |
| Function Description | Six lncRNAs had significant prognostic values, and their cumulative risk score indicated that this 6-lncRNA signature independently predicted RFS in BC patients.High-risk patients exhibited a poorer prognosis than low-risk patients did. Additionally, the 6-lncRNA signature showed a significant correlation with BC clinicopathological characteristics, which indicates that it could be used for effective risk stratification. |
| Pubmed ID | 31892978 |
| Year | 2020 |
| Title | Identification of a six-lncRNA Signature Based on a Competing Endogenous RNA Network for Predicting the Risk of Tumour Recurrence in Bladder Cancer Patients |
External Links
| Links for GLIS3-AS1 | GenBank HGNC NONCODE |
| Links for bladder cancer | OMIM COSMIC |